A drug to treat retinal diseases with drops instead of injections

December 13, 2017, Spanish Foundation for Science and Technology (FECYT)
A drug to treat retinal diseases with drops instead of injections
Sylentis SYL136001v10 drug is a small interfering RNA capable of penetrating the cells of the retina and blocking the formation of new blood vessels by intravitreal drops. Credit: PharmaMar

The Spanish firm Sylentis has developed a compound to treat diseases of the retina including age-related macular degeneration and diabetic retinopathy. The treatment is administered by ophthalmic drops instead of intraocular injections and has been tested in animals. It is a small interfering RNA capable of penetrating the cells of the retina and blocking the formation of new blood vessels.

The drug SYL136001v10, developed by PharmaMar, is still in the preclinical phase. "Its effectiveness has been proven in animal models and trials with humans will begin at the end of 2018," said Covadonga Pañeda, R+D Manager at Sylentis. Pañeda is the main author of a study on SYL136001v10, which was presented at the end of September at the XIII Annual Meeting of the Oligonucleotides Therapeutics Society, held in Bordeaux (France).

Pañeda says, "This compound is a small interfering RNA (siRNA) designed to silence the expression of NRARP, a protein that controls the formation of new blood vessels in the ." In this way, she says, "the drug exerts its action by entering the cells of the retina, where it prevents the synthesis of this protein and blocks the formation of new vessels, which is one of the fundamental characteristics of degenerative diseases of the retina."

The compounds currently used to treat these diseases are based on large antibodies that cannot penetrate from the ocular surface to the retina, so they must be administered by intravitreal injections. "Patients suffering from or have to go to the hospital where the treatments are performed with ocular injections, which is annoying and painful, and also involves a significant financial investment for the health system," says Covadonga Pañeda.

However, she notes, "siRNA, like SYL136001v10, are up to 10 times smaller than these treatments. Their size allows them to penetrate the retina and inhibit the formation of new blood vessels after their application in ophthalmic drops, as we have shown in animal models. In particular, efficacy studies have shown that the reduction of NRARP in the retina by means of siRNA leads to the regression of angiogenic retinal lesions and that the observed reductions are equivalent to those of anti-VEGF, which is the current treatment standard for these diseases with ocular injections."

The firm, located in Tres Cantos (Madrid), plans to take charge of the first clinical efficacy studies. Once the proof of concept in humans has been demonstrated, it will try to license the drug to a multinational.

Explore further: Researchers identify new target for abnormal blood vessel growth in the eyes

Related Stories

Researchers identify new target for abnormal blood vessel growth in the eyes

April 11, 2017
A team led by Massachusetts Eye and Ear researchers has identified a novel therapeutic target for retinal neovascularization, or abnormal blood vessel growth in the retina, a hallmark of advanced diabetic eye disease (proliferative ...

Growth factor shown to protect the retina in early stage diabetes

February 2, 2017
Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have shown that a slight increase in transforming growth factor beta (TGF-β), which is present in preclinical animal models with diabetic ...

Caring for blindness: A new protein in sight?

April 21, 2015
Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. ...

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina

July 24, 2017
A research team from the Schepens Eye Research Institute of Massachusetts Eye and Ear has successfully prevented mice from developing angiogenesis of the retina—the sensory tissue at the back of the eye—using gene-editing ...

GEN reports on ocular therapeutics targeting the retina

September 10, 2012
Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN). Because current retinal disease treatments only improve vision for six to eight weeks, ...

Study finds novel therapy that may prevent damage to the retina in diabetic eye diseases

July 27, 2012
Researchers at the University of Michigan Kellogg Eye Center have identified a compound that could interrupt the chain of events that cause damage to the retina in diabetic retinopathy. The finding is significant because ...

Recommended for you

Scientists gain new insight on how antibodies interact with widespread respiratory virus

February 22, 2018
Scientists have found and characterized the activity of four antibodies produced by the human immune system that target an important protein found in respiratory syncytial virus (RSV), according to new research published ...

Study reveals how kidney disease happens

February 22, 2018
Monash researchers have solved a mystery, revealing how certain immune cells work together to instigate autoimmune kidney disease.

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.